BGI Genomics launched the DMD DUP Test using long-read whole-genome sequencing to resolve duplication structure, map breakpoints, and support more accurate variant interpretation for Duchenne muscular dystrophy families.

BGI Genomics is the world's leading integrated solutions provider of precision medicine, now serving customers in more than 100 countries, involving over 2,300 medical institutions. Relying on cutting-edge sequencing and bioinformatics technology, we provide our customers with expert and affordable clinical molecular diagnostic solutions and high-throughput sequencing (NGS) research services.